Fig. 2. 5-FU activates the WNT/β-catenin pathway in murine CRC.

a Immunoblots of indicated proteins in Apc^Min/+/Lgr5^EGFP tumor organoids with or without 5-FU treatment (1.5 μg/ml, 48 h). b Confocal images of β-catenin (red) in Apc^Min/+/Lgr5^EGFP tumor organoids with or without 5-FU treatment. The percentage of β-catenin^/+ cells (n = 4 biologically independent samples per group) and the mean intensities (n = 3 biologically independent samples per group) were quantified. Scale bar = 50 μm. c β-galactosidase staining of the tumor organoids derived from Apc^Min/+/Axin2^LACZ mice with or without 5-FU treatment. Scale bar = 100 μm. d Time-course analysis of β-catenin expression in Apc^Min/+/Lgr5^EGFP tumor organoids with or without 5-FU treatment and quantification of mean intensities. Scale bar = 100 μm. e, f Apc^Min/+/Lgr5^EGFP mice were treated with vehicle or 5-FU (25 mg/kg, 3 weeks). e Hematoxylin and eosin staining and DAB staining of β-catenin and Lgr5 (GFP) in sections of intestinal tumors of Apc^Min/+/Lgr5^EGFP mice treated with vehicle or 5-FU. Scale bar = 100 μm. f Linear regression curve showing Lgr5 and β-catenin expression in tumors of Apc^Min/+/Lgr5^EGFP mice treated with 5-FU. The mean intensities were measured by Zen software 3.1. (n = 21 fields examined over four biologically independent animals per group) Data are mean ± s.d., two-sided Student’s t-test, **p < 0.01, ***p < 0.001. Source data are provided as a Source data file.